Natera, Inc. (NASDAQ:NTRA – Get Free Report) CFO Michael Burkes Brophy sold 782 shares of the stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $260.49, for a total transaction of $203,703.18. Following the completion of the sale, the chief financial officer directly owned 56,714 shares in the company, valued at approximately $14,773,429.86. This represents a 1.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Michael Burkes Brophy also recently made the following trade(s):
- On Wednesday, July 29th, Michael Burkes Brophy sold 1,863 shares of Natera stock. The stock was sold at an average price of $249.38, for a total transaction of $464,594.94.
- On Tuesday, July 28th, Michael Burkes Brophy sold 2,419 shares of Natera stock. The stock was sold at an average price of $253.96, for a total transaction of $614,329.24.
- On Monday, May 4th, Michael Burkes Brophy sold 482 shares of Natera stock. The shares were sold at an average price of $210.49, for a total value of $101,456.18.
- On Friday, May 1st, Michael Burkes Brophy sold 313 shares of Natera stock. The shares were sold at an average price of $206.16, for a total value of $64,528.08.
Natera Price Performance
Natera stock opened at $253.82 on Thursday. The stock has a market cap of $36.35 billion, a PE ratio of -155.72 and a beta of 1.51. The stock’s fifty day moving average is $244.16 and its two-hundred day moving average is $221.65. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $288.04.
Key Natera News
- Neutral Sentiment: Most notably, CFO Michael Burkes Brophy sold 5,064 shares for approximately $1.28 million, while CEO Steven Leonard Chapman sold 5,770 shares for about $1.48 million. Both executives cited pre-arranged Rule 10b5-1 trading plans and said the sales were made to cover tax-withholding obligations related to vested equity awards, reducing the likelihood that the transactions signal a loss of confidence. CFO SEC filing CEO SEC filing
- Neutral Sentiment: Insiders John Fesko and Solomon Moshkevich also sold a combined 3,927 shares worth approximately $1.01 million under similar pre-arranged plans to meet tax obligations. They retained substantial holdings after the sales, further limiting the negative interpretation. Fesko SEC filing Moshkevich SEC filing
- Negative Sentiment: The concentration of sales by the CEO, CFO and other insiders may nevertheless create modest short-term selling pressure or raise valuation concerns, particularly because NTRA remains well below its 52-week high and carries a negative trailing price-to-earnings ratio. However, the filings contain no new operational or financial warning.
Analysts Set New Price Targets
NTRA has been the subject of several recent analyst reports. Morgan Stanley boosted their target price on Natera from $250.00 to $310.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Sanford C. Bernstein initiated coverage on shares of Natera in a research note on Friday, June 26th. They issued an “outperform” rating and a $310.00 price target on the stock. TD Cowen reissued a “buy” rating on shares of Natera in a report on Wednesday, July 15th. JPMorgan Chase & Co. boosted their price objective on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Finally, Robert W. Baird set a $265.00 target price on shares of Natera in a report on Friday, May 8th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $267.83.
Read Our Latest Report on NTRA
Institutional Trading of Natera
A number of large investors have recently made changes to their positions in the company. Elevation Wealth Partners LLC purchased a new position in Natera during the 2nd quarter worth approximately $30,000. Reflection Asset Management purchased a new stake in Natera in the fourth quarter valued at approximately $29,000. Palladiem LLC purchased a new stake in Natera in the fourth quarter valued at approximately $31,000. Bank of Jackson Hole Trust boosted its holdings in shares of Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 83 shares during the period. Finally, International Assets Investment Management LLC grew its position in shares of Natera by 132.9% during the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after acquiring an additional 97 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.
About Natera
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Featured Articles
- Five stocks we like better than Natera
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
